Authors
Latest:
Dr. Bardia on the Need to Develop Additional Therapies in Metastatic TNBCAditya Bardia, MD, MPH, discusses the need to develop additional therapies for patients with metastatic triple-negative breast cancer.
Latest:
Treatment Advances in HR+ Advanced Breast CancerAditya Bardia, MD, MPH, discusses the current standard of care for HR+ advanced breast cancer and reacts to treatment advances with the availability of CDK4/6 inhibitors.
Latest:
Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLCThe panel discusses treatment considerations for consolidation durvalumab.
Latest:
Keeping Ahead of Oncology Advances Requires VigilanceAditya V. Shreenivas, MD, MSCR, says a habit of continuous learning is the ideal way to stay informed about the latest data.
Latest:
Dr. Suarez Mora On Sequential Sampling of IP Fluid During ChemotherapyAdria Suarez Mora, MD, second-year fellow at UPMC Magee-Womens Hospital, discusses how sequential sampling of intraperitoneal fluid during chemotherapy help better define the immunogenic effects of the treatment.
Latest:
Dr Wiestner on an Extended Follow-Up Study of Resistance Mutations With Acalabrutinib in CLLAdrian Wiestner, MD, PhD, sheds light on resistance mutations in patients with chronic lymphocytic leukemia who were treated with acalabrutinib.
Latest:
Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral CentersPanelists discuss how community providers can implement strategies and utilize resources to effectively connect patients to referral centers for chimeric antigen receptor T-cell therapy, while addressing how to initiate conversations about the therapy and counsel patients regarding potential adverse events.
Latest:
Impairment-Driven Cancer Rehabilitation Improves Survivors' Quality of LifeThe lack of comprehensive rehabilitation services is a profound source of unnecessary suffering for survivors.
Latest:
Dr Phillips on the Shifting Treatment Paradigm For CAR T-Cell Therapy in LBCLAdrienne Phillips, MD, MPH, discusses the impact of CAR T-cell therapy on the treatment paradigm for patients with large B-cell lymphoma, highlighting key advancements in the decision-making process for CAR T-cell therapy selection.
Latest:
Dr. Ribeiro on the Role of Surgery in Pancreatic CancerAfonso Ribeiro, MD, discusses the role of surgery in treating patients with pancreatic cancer.
Latest:
Dr. Barzi on Combination Regorafenib and Pembrolizumab in MSS CRCAfsaneh Barzi, MD, PhD, discusses the combination of regorafenib and pembrolizumab in patients with microsatellite stable colorectal cancer.
Latest:
Ã…ge Schultz, DVM, PhD, Discusses the Cost of Supportive Care MedicineÃ…ge Schultz, DVM, PhD, executive director, Multinational Association of Supportive Care in Cancer (MASCC), discusses pain management and the cost of supportive care medicine.
Latest:
Dr. Paner on HORIZON Trial in Multiple MyelomaAgne Paner, MD, director, discusses the phase II HORIZON trial in relapsed/refractory multiple myeloma.
Latest:
Dr. Janus on the Role of Moxetumomab Pasudotox in Hairy Cell LeukemiaAgnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.
Latest:
Novel Agents Signal Progress in the Management of Platinum-Resistant Ovarian CancerThe evaluation of noncytotoxic agents for the treatment of epithelial ovarian cancer has produced encouraging findings in recent months, which has led to the approval of new agents with novel mechanisms of action and continuing studies into many more potential therapies.
Latest:
It's Time to Tackle the Evidence Gap in Lymphoid CancersAlthough CLL is the most common chronic leukemia, there remains no single agreed-upon standard of care for first-line treatment.
Latest:
Dr Tarhini on the Combination of High-Dose Bolus IL-2 and CTLA-4 Inhibition in Advanced MelanomaAhmad Tarhini, MD, PhD, discusses the hypothesis for investigating high-dose bolus IL-2 plus an anti–CTLA-4 agent in patients with advanced melanoma.
Latest:
TRT in Patients With Prostate Cancer on Active Surveillance: Are We Really Putting Gas on Fire?Investigators hypothesized that testosterone replacement does not have a negative impact on the oncologic outcomes of treatment-naive patients with prostate cancer on surveillance and they performed a retrospective review of an institutional active surveillance prostate cancer database.
Latest:
Dr. Galal on Managing AEs Linked With CAR T-Cell TherapyAhmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the management of adverse events (AEs) associated with CAR T-cell therapy.
Latest:
Dr. Al-Niaimi Discusses Cytoreductive Surgery in Ovarian CancerAhmed N. Al-Niaimi, MD, assistant professor of obstetrics and gynecology, University of Wisconsin School of Medicine and Public Health, discusses cytoreductive surgery in ovarian cancer.
Latest:
Dr Kaseb on the Investigation of Adjuvant Atezolizumab and Bevacizumab in Early-Stage HCCAhmed O. Kaseb, MD, discusses the significance of results from the phase 3 IMbrave050 trial of adjuvant atezolizumab and bevacizumab for patients with early-stage hepatocellular carcinoma.
Latest:
Dr. Dogan on Updated WHO Classifications in DLBCLAhmet Dogan, MD, PhD, chief of Hematopathology Service, Departments of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center, discusses the updated World Health Organization (WHO) classification and how it impacts treatment decisions for patients with diffuse large B-cell lymphoma (DLBCL).
Latest:
NOW Initiative: Payer & Provider Collaborations in Oncology Benefits ManagementPayers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial relationship between payers and oncologists through a collaborative model.
Latest:
Dr. He on the Results of the LEGACY Study Examining Y-90 in HCCRuth Aiwu He, MD, PhD, discusses the results of the LEGACY study in patients with hepatocellular carcinoma.
Latest:
Dr He on the Evaluation of Camrelizumab Plus Rivoceranib in Unresectable HCCAiwu Ruth He, MD, PhD, discusses the evaluation of camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.
